Abstract: |
There is a common notion based on historic data that testosterone therapy (TTH) has negative effects on the prostate. More recent data, however, refutes this notion. This conflict is due in part to the saturation model, which suggests that at lower testosterone (T) levels, increasing T levels can have downstream effects. Above this threshold, the androgen receptors are maximally stimulated and, thus, further increases in T do not have further effects on the prostate. This explains why at low T levels TTH may increase prostate-specific antigen (PSA) l or prostate volume, but this is not seen in men with T levels above the saturation point. With regard to lower urinary tract symptoms (LUTS), the data suggests that there is not an increase in symptoms with initiation of TTH based on either subjective report or objective measures. The topic of prostate cancer (PCA) development is of particular interest given the fact that androgen deprivation can be used to treat PCA. The current data demonstrates no increase in PCA risk in men on TTH. Conversely, patients with testosterone deficiency (TD) may have more aggressive PCA. All potential TTH candidates need to be thoroughly counseled on the effects of TTH on prostate events. © Springer Nature Switzerland AG 2021. |